AMPE - Ampio Pharmaceuticals, Inc.
| Previous Close | 0.6801 |
| Open | 0.6790 |
| Bid | 0.6900 x 800 |
| Ask | 0.7084 x 800 |
| Day's Range | 0.6700 - 0.7141 |
| 52 Week Range | 0.2600 - 1.3100 |
| Volume | 851,429 |
| Avg. Volume | 1,088,496 |
| Market Cap | 109.481M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0780 |
| Earnings Date | Mar 15, 2020 - Mar 19, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- Insider Monkey
Here is What Hedge Funds Think About Ampio Pharmaceuticals, Inc. (AMPE)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- PR Newswire
Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion™ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and its manufacturing facility.
- PR Newswire
Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility
ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of AmpionTM to treat Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced updates of the continued progress with their Phase III AP-013 clinical trial and their "state-of-the-Art" manufacturing facility. "It is important to note," Ms. Cherevka continued, "in the three randomized single-injection studies previously run by the Company, both reduction in pain and improvement in function were significantly greater for KL 4 patients treated with Ampion vs saline.
- PR Newswire
Ampio Retains Legal Counsel for Transaction Advisory Committee
ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled "Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced that Cooley LLP has been engaged to represent Ampio with respect to a potential strategic transaction, as well as related matters.
- PR Newswire
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
ENGLEWOOD, Colo. , Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three ...
- PR Newswire
Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee
ENGLEWOOD, Colo., Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase three clinical trial titled, "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced that the Company has retained Torreya Partners LLC as a financial advisor and has appointed Willam Bindley and Bruce E. Terker to a newly formed Transaction Advisory Committee (TAC).
- PR Newswire
Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor
ENGLEWOOD, Colo., July 11, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that its Audit Committee and Board of Directors appointed Moss Adams LLP as the Company's new independent auditor. Moss Adams has served for over 100 years as a fully integrated professional services firm with over 3,200 professionals across more than 25 locations in the western United States.
- PR Newswire
Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer
ENGLEWOOD, Colo., July 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that Dan Stokely has been appointed as Chief Financial Officer. Dan Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant.
- PR Newswire
Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering
The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial, titled "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with pain Due to Severe Osteoarthritis of the Knee," pursuant to its recently announced Special Protocol Assessment and for other general corporate purposes. The shares of common stock in this offering were offered on a reasonable best efforts, any and all basis pursuant to an effective shelf registration statement.
- PR Newswire
Ampio Pharmaceuticals Announces Pricing of Public Offering
The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial pursuant to its recently announced Special Protocol Assessment and other general corporate purposes. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the exclusive placement agent for this transaction.
- PR Newswire
Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Ampio expects to grant the underwriters a 45-day option to purchase additional shares of common stock offered in the public offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
- PR Newswire
Ampio Regulatory and Clinical Update
According to Michael Macaluso, Ampio CEO, "The Company has identified and engaged 15 clinical sites for the trial (AP-013) and patient identification is underway. This pivotal trial seeks to enroll approximately 1,000 patients, with an interim look, to allow sample size adjustments, if required.
- PR Newswire
Ampio Clinical, Regulatory and Corporate Update
Clinical: The results of the AP-003-C open label extension study outlining the safety and efficacy of repeat injections of Ampion™ in patients with severe osteoarthritis-of-the-knee (OAK) have been accepted as a podium presentation at the 83rd Annual Meeting of the Western Orthopedic Association (WOA) in Monterey, CA., held from July 31st to August 3rd, 2019. The WOA meeting was developed primarily for orthopedic and trauma surgeons and allied health professionals. The WOA Committee selected multiple research papers and invited nationally respected speakers to present practice-related techniques and findings in orthopedic surgery that cover a variety of specialty orthopedic disciplines and advances in treatment. The Ampion study is entitled "Investigating Repeated Intra-Articular Injections of The Anti-Inflammatory Compound LMWF-5A (Ampion) In Adults with Severe Osteoarthritis: An Open-Label Extension Study" and will be presented by orthopedic surgeon, John Schwappach, MD.
- PR Newswire
Ampio Pharmaceuticals Provides Regulatory Update
ENGLEWOOD, Colo., April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurrence on the trial design. The Company agreed with the comments they received from the FDA and immediately sent a revised SPA to the FDA for review.
- PR Newswire
Ampio Pharmaceuticals Provides Corporate Update
ENGLEWOOD, Colo., March 26, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that on March 11, 2019, the Company resubmitted a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a confirmatory Phase III clinical trial of its biological drug, Ampion™, for the treatment of patients afflicted with Osteoarthritis of the Knee (OAK). Mr. Macaluso, Ampio's CEO added, "After a series of interactions with the FDA, we believe we have addressed and answered all questions regarding trial design. The FDA confirmed they would respond to our SPA submission no later than April 25, 2019.
- PR Newswire
Ampio Updates Regulatory Status for Ampion
ENGLEWOOD, Colo., March 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™. Food and Drug Administration (FDA) provided guidance that Ampio should complete an additional trial of Kellgren Lawrence Grade 4 (KL 4) osteoarthritis of the knee (OAK) patients with concurrent controls that would be carried out under a Special Protocol Assessment (SPA). Ampio presented the FDA with two different forms of concurrent controls the company was considering in trial design: a saline injection or a sham injection, both previously identified by the FDA as possible controls.
- GlobeNewswire
Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire
Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA
ENGLEWOOD, Colo., Feb. 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company's submission of a proposed trial design for the treatment of KL4 Osteoarthritis patients with Ampion™. Michael Macaluso, Ampio's CEO, explained: "A SPA is an agreement between the sponsor and FDA that the trial design, clinical endpoints, and statistical analyses could support marketing approval.
